Shares of Spring Bank Pharmaceuticals Inc (NASDAQ:SBPH) have earned an average rating of “Buy” from the six brokerages that are covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and four have assigned a buy recommendation to the company. The average twelve-month target price among brokers that have covered the stock in the last year is $26.33.
A number of brokerages have commented on SBPH. ValuEngine lowered Spring Bank Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Friday, December 1st. Cantor Fitzgerald set a $29.00 price target on Spring Bank Pharmaceuticals and gave the stock a “buy” rating in a research report on Thursday, November 16th. Chardan Capital restated a “buy” rating on shares of Spring Bank Pharmaceuticals in a research report on Monday, November 6th. Finally, B. Riley began coverage on Spring Bank Pharmaceuticals in a research report on Monday, November 6th. They issued a “buy” rating and a $30.00 price target on the stock.
Shares of Spring Bank Pharmaceuticals (NASDAQ:SBPH) opened at $12.09 on Wednesday. Spring Bank Pharmaceuticals has a twelve month low of $7.69 and a twelve month high of $18.93. The firm has a market capitalization of $153.99, a price-to-earnings ratio of -4.40 and a beta of 0.75.
ILLEGAL ACTIVITY WARNING: “Spring Bank Pharmaceuticals Inc (SBPH) Given Consensus Rating of “Buy” by Brokerages” was first reported by American Banking News and is owned by of American Banking News. If you are accessing this story on another site, it was illegally stolen and reposted in violation of United States & international copyright laws. The legal version of this story can be accessed at https://www.americanbankingnews.com/2018/02/14/spring-bank-pharmaceuticals-inc-sbph-given-consensus-rating-of-buy-by-brokerages.html.
About Spring Bank Pharmaceuticals
Spring Bank Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of a class of therapeutics using its small molecule nucleic acid hybrid (SMNH) chemistry platform. The Company is developing its SMNH product, SB 9200, for the treatment of viral diseases.
Receive News & Ratings for Spring Bank Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spring Bank Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.